Update information

May 2024: The wording in recommendation 1.1 has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.

November 2023: The wording in recommendation 1.1 and section 2 has been updated to include procurement information about natalizumab biosimilars.

March 2014: Implementation section was updated to clarify that natalizumab is recommended as an option for treating highly active relapsing–remitting multiple sclerosis. Additional minor maintenance update also carried out.

March 2012: Minor maintenance.

ISBN: 978-1-4731-6144-3